Abstract 212: High-resolution barcoding in patient-derived xenografts of triple-negative breast cancer reveals reversible chemoresistance conferred by non-mutational mechanisms
Gloria V. Echeverria(Baylor College of Medicine), Helen Piwnica‐Worms(Centre for Cancer Biology), Zhongqi Ge(The University of Texas MD Anderson Cancer Center), Christopher A. Bristow(The University of Texas MD Anderson Cancer Center), Jeffery T. Chang(The University of Texas Health Science Center at Houston), Xinhui Zhou(Guangxi Academy of Agricultural Science), Shirong Cai(Sun Yat-sen University), Yuting Sun(The University of Texas MD Anderson Cancer Center), Prabjhot Mundi(Columbia University Irving Medical Center), Sabrina L. Jeter-Jones(The University of Texas MD Anderson Cancer Center), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center), Andrea Califano(Columbia University Irving Medical Center), Joseph R. Marszalek(The University of Texas MD Anderson Cancer Center), Alessandro Carugo(The University of Texas MD Anderson Cancer Center), Timothy P. Heffernan(The University of Texas MD Anderson Cancer Center), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Yizheng Tu(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Aaron McCoy(The University of Texas MD Anderson Cancer Center), Sahil Seth(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991